IMI vs Natera

IMI and Natera are two companies in the healthcare sector that are frequently compared by investors. IMI, or Integrated Micro-Electronics Inc., is a global provider of electronics manufacturing services, while Natera is a pioneer in genetic testing and molecular diagnostics. Both companies have shown strong growth potential and have attracted significant investor interest. Investors often weigh the pros and cons of investing in these stocks, considering factors such as revenue growth, profitability, and market positioning. This comparison of IMI versus Natera stocks explores the key differences and similarities between these two healthcare companies.

IMI or Natera?

When comparing IMI and Natera, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between IMI and Natera.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. IMI has a dividend yield of 1.63%, while Natera has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. IMI reports a 5-year dividend growth of -7.81% year and a payout ratio of 29.10%. On the other hand, Natera reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with IMI P/E ratio at 18.43 and Natera's P/E ratio at -54.25. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. IMI P/B ratio is 4.27 while Natera's P/B ratio is 18.95.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, IMI has seen a 5-year revenue growth of 0.20%, while Natera's is 1.11%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with IMI's ROE at 23.85% and Natera's ROE at -36.74%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are £1774.00 for IMI and $128.07 for Natera. Over the past year, IMI's prices ranged from £1429.00 to £1911.00, with a yearly change of 33.73%. Natera's prices fluctuated between $36.90 and $133.54, with a yearly change of 261.89%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.